Real‐world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL ( TREatment of ATopic eczema, the Netherlands) registry
Abstract Background Evidence on the (long‐term) safety of systemic immunomodulating therapies in atopic dermatitis (AD) generated by real‐world data is sparse. Objectives To describe real‐world reported adverse drug reactions (AEs) related to systemic immunomodulating therapy in patients with AD and to compare the incidence rates of AEs with the Summaries of Product Characteristics (SmPCs). Methods We conducted an observational prospective multi‐centre cohort study, using the TREAT NL registry. All severe AEs, AEs of special interest and serious AEs in adult and paediatric patients on systemic... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Journal of the European Academy of Dermatology and Venereology ; volume 38, issue 3, page 530-542 ; ISSN 0926-9959 1468-3083 |
Verlag/Hrsg.: |
Wiley
|
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-29222168 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1111/jdv.19643 |